HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $58 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a price target of $58.
June 07, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Mirum Pharmaceuticals and maintained a price target of $58, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $58 by HC Wainwright & Co. suggests strong confidence in Mirum Pharmaceuticals' future performance. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100